ArticleJournal of virology2026
Modeling human enterovirus A71 infection using an intestinal microphysiological system.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Enterovirus A71 (EV-A71), a causative virus of hand, foot, and mouth disease, primarily infects and replicates in the intestine and, in severe cases, spreads to the central nervous system, leading to neurological complications. Therefore, suppressing viral replication in the intestine is important to prevent severe complications. However, the intestinal pathophysiological changes in EV-A71-infected patients remain poorly understood. In this study, we aimed to examine the intestinal response to EV-A71 infection using the intestinal microphysiological system (MPS) we previously developed using human pluripotent stem cells and microfluidic devices. The viral titers were detectable in the cell culture supernatant of the intestinal MPS for 14 days after the viral infection. Despite this, EV-A71 infection did not induce significant morphological changes in the intestinal MPS or alter the expression of epithelial cell markers, suggesting that the virus can infect the intestinal MPS without causing intestinal epithelial damage. In addition, we found that the secretion of interferons (IFNs) in the cell culture supernatant was not increased by viral infection. Interestingly, treatment with recombinant IFNs increased the expression of innate immune response-related genes and reduced viral mRNA levels. A strong association was observed between EV-A71 infection and IFN signaling in the intestinal MPS. We believe that the intestinal MPS would be a valuable platform for studying EV-A71 infection and evaluating antiviral strategies.IMPORTANCEEnterovirus A71 (EV-A71), a major cause of hand, foot, and mouth disease, primarily replicates in the intestine and can spread to the central nervous system, causing severe neurological complications. Suppressing intestinal replication is therefore critical, yet the intestinal pathophysiology of EV-A71 remains poorly understood. Here, we examined EV-A71 infection using a human pluripotent stem cell-derived intestinal microphysiological system (MPS). Viral titers were detectable in the culture supernatant for 14 days. However, EV-A71 did not induce significant morphological changes or alter epithelial marker expression, indicating persistent infection without intestinal damage. Additionally, EV-A71 infection did not enhance interferon (IFN) secretion. Treatment with recombinant IFNs increased innate immune gene expression and reduced viral mRNA, demonstrating the key role of IFN signaling in restricting infection. These findings suggest that the intestinal MPS would be a useful platform for studying EV-A71 infection and antiviral strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.